Floatz logo

Idarubicin

Acute Myeloblastic Leukemia With Maturation

Bruno C. MedeirosSmall moleculePhase 3Dormant
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Acute Myeloblastic Leukemia With Maturation cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Stanford University
Phase 3BBB
CYTARABINE
Northwestern University
Phase 3BBB
Daunorubicin
National Cancer Institute (NCI)
Phase 3BBB
Cyclophosphamide
ECOG-ACRIN Cancer Research Group
Phase 3BBB
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 2BBB

View all 49 →

Same molecule, other indications

Idarubicin is also rated in:

acute promyelocytic leukemiaDormant
A
Indicative ·
81 / 100
View asset →
acute myeloid leukemia with 11q23 abnormalitiesDormant
BBB
Indicative ·
76 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →